Perfect Potent API Processing: Handling Hazardous Drug Actives Effectively

A Q&A with David O’Connell, PCI Pharma Services

The journey from discovery laboratory to pharmacy shelf is long and arduous, particularly for highly potent APIs, which must be handled in compliance with complex regulatory requirements at each stage of the journey.

Pharmaceutical companies looking for a Contract Development and Manufacturing Organization (CDMO) to help them navigate should look for one with a combination of true expertise, capabilities and a robust assessment process giving all molecules a “potent passport” according to David O’Connell, Director of Pharmaceutical Development at PCI Pharma Services.